ArticleInternational journal of molecular sciences2016

Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.

Thorsten H Ecke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.